Human Diabetic Primary Gallbladder Fibroblast Cells
Quick Actions
Product Overview
Description
Human Diabetic Primary Gallbladder Fibroblast Cells are cryopreserved primary fibroblast cells intended for in vitro studies of diabetes-associated cellular dysfunction, tissue remodeling, signaling, and pharmacology. Early-passage use is recommended to reduce phenotype drift and preserve application-relevant behavior.
Guarantee expansion for a minimum of 2-6 population
doublings.
IMPORTANT: Quality warranty requires use of NeoBioPharma media. Biohazardous material despite negative pathogen testing. Quality claims must be reported within 1 month.
Key Features
Catalog Number: NBPDF006
Product Format: Frozen
Vial Cell Number: > 5x10[5] cells/vial
Passage:1(P1)
Storage: Liquid Nitrogen, Vapor Phase
Intended Use: Research use only (RUO)
Characterization Markers
- Characterized by spindle morphology under light microscopy.
- Negative for von Willebrand Factor (vWF) , Cytokeratin 18,
and alpha-smooth muscle actin .
- Isolated and characterized to ensure fibroblast purity and identity.
Quick Facts
Product Type
Human Type II Diabetes Endothelial Cells
Viability
>95% viable (Trypan Blue exclusion)
Applications
Diabetic Cholecystopathy: Diabetes is a major ris…
Availability
In Stock • Global Shipping
Technical Specifications
Primary Applications
Applications & Use Cases
Primary Applications
Diabetic Cholecystopathy: Diabetes is a major risk factor for gallstones (cholelithiasis) and "acalculous" gallbladder disease. These cells help study how hyperglycemia affects gallbladder motility and wall stiffness. Wound Healing: Diabetic fibroblasts often exhibit delayed proliferation and altered cytokine secretion compared to non-diabetic controls. Drug Screening: Testing anti-fibrotic agents (e.g.
Suitable for diabetic cholecystopathy: diabetes is a major risk factor for gallstones (cholelithiasis) and "acalculous" gallbladder disease. these cells help study how hyperglycemia affects gallbladder motility and wall stiffness. wound healing: diabetic fibroblasts often exhibit delayed proliferation and altered cytokine secretion compared to non-diabetic controls. drug screening: testing anti-fibrotic agents (e.g. studies and research applications
metformin
Suitable for metformin studies and research applications
GLP-1 agonists) on cells that mimic the diabetic microenvironment.
Suitable for glp-1 agonists) on cells that mimic the diabetic microenvironment. studies and research applications
Research Areas
In Vitro Studies
Cell culture and screening applications
Molecular Biology
Gene expression & signaling studies
Drug Discovery
Screening & validation studies
Disease Modeling
Pathophysiology research
Support & Resources
Technical Support
Our experts are available for technical questions and protocol assistance.
Contact Support
